COMT might act as an anti-invasive agent on ER + breast cancer also through its newly discovered interplay with MET signaling via its interacting partner, SPINT2, leading to the inhibition of this pro-tumorigenic pathway. This evidence concerns the gene MET and breast carcinoma.